BiXAb® technology (for bi- and multi-specific antibodies)

	Next higher product group	antibody technology_o
	Status	2019-01-15 production/use existent
	Organisation	Biomunex Pharmaceuticals SAS

Record changed: 2024-12-03

Picture Berlin Partner Voices Surjo Soekadar 650x200px

More documents for antibody technology_o

[1] Ipsen S.A.. (12/3/24). "Press Release: Ipsen and Biomunex Announce Exclusive Global Licensing Agreement for First-in-Class MAIT Cell Engager in Immuno-oncology". Paris....
[2] CDR-Life AG. (4/13/22). "Press Release: CDR-Life Announces $76 Million Raised in Series A Funding". Zürich....
[3] Biomunex Pharmaceuticals SASU. (2/7/22). "Press Release: Biomunex and Institut Curie Pursue Strategic Collaboration for Development of Disruptive Non-conventional T Cell Redirection Approach to Treating Cancer". Paris & Cambridge, MA....
[4] Biomunex Pharmaceuticals SASU. (2/16/21). "Press Release: Biomunex Pharmaceuticals Signs Strategic License and Co-Development Agreement with Onward Therapeutics for Proprietary Bispecific Antibody Program". Paris & Cambridge, MA....
[5] Polyneuron Pharmaceuticals AG. (9/16/20). "Press Release: Polyneuron Extends Series A to CHF 36.5 Million with Additional CHF 14 Million". Basel....
[6] Biotalys N.V.. (3/5/20). "Press Release: Biotalys Announces Second Closing of €45 Million Series C Financing Round". Ghent....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)